Elixir Pharmaceuticals' Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not Well-Controlled on Metformin Alone

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today positive results from a pivotal phase III clinical study of the Company’s oral formulation of mitiglinide administered in combination with metformin for the treatment of patients with type 2 diabetes. The study achieved statistical and clinical significance in its primary efficacy endpoint. Patients receiving the combination of twice-daily mitiglinide and metformin experienced a statistically significant additional reduction in hemoglobin A1c (HbA1c) levels compared to patients receiving metformin alone. HbA1c is a measure of average blood sugar over time and takes into account the baseline level of sugar (fasting plasma glucose) and the rises that occur after a meal (post-meal glucose). The final results from this study will be submitted for presentation to an upcoming national scientific meeting.

Back to news